Exploring the Key Genes Associated with Breast Cancer Radiotherapy Sensitivity Based on the Stromal-immune Score and Analysis of the WGCNA and CeRNA Network

Overview

Journal Heliyon

Date 2025 Jan 16

PMID 39816347

Authors

Xiaoyue Sun

Chihua Wu

Yao Lin

Shengwei Zhang

Xinchen Zhao

Xiaoshan Wang

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer is a highly malignant disease worldwide, but there are currently no sufficient molecular biomarkers to predict patient prognosis and guide radiotherapy. The tumor microenvironment (TME) is an important factor affecting tumor biological function, and changes in its composition are equally relevant to tumor progression and prognosis during radiotherapy.

Methods: Here, we performed bioinformatic analyses using data obtained from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases to screen for molecular biomarkers related to the TME that may influence radiotherapy sensitivity. By combining immune scores and stromal scores and performing weighted coexpression network analysis (WGCNA), we identified key modules and hub genes to construct competing endogenous RNA (ceRNA) networks. Then, key pathways and genes were identified using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Furthermore, we explored the effect of THBS2 on the malignant phenotype of breast cancer through cellular experiments.

Results: Genes in the PI3K-AKT pathway in the blue module were significantly enriched. Among the hub genes in the blue module, COL1A1, COL1A2, COL6A3, THBS2 and PDGFRB were negatively associated with RT sensitivity. Cellular experiments confirmed that knockdown of THBS2 inhibited the proliferation and invasion of breast cancer cells.

Conclusion: These findings may provide new insights into the mechanisms of radiotherapy sensitivity in breast cancer patients, offering hope for the discovery of new therapeutic targets.

References

Cheetham S, Gruhl F, Mattick J, Dinger M . Long noncoding RNAs and the genetics of cancer. Br J Cancer. 2013; 108(12):2419-25. PMC: 3694235. DOI: 10.1038/bjc.2013.233. View

Kramer C, Vangangelt K, van Pelt G, Dekker T, Tollenaar R, Mesker W . The prognostic value of tumour-stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review. Breast Cancer Res Treat. 2018; 173(1):55-64. PMC: 6394568. DOI: 10.1007/s10549-018-4987-4. View

Kovacs A, Stenmark Tullberg A, Ronnerman E, Holmberg E, Hartman L, Sjostrom M . Effect of Radiotherapy After Breast-Conserving Surgery Depending on the Presence of Tumor-Infiltrating Lymphocytes: A Long-Term Follow-Up of the SweBCG91RT Randomized Trial. J Clin Oncol. 2019; 37(14):1179-1187. DOI: 10.1200/JCO.18.02157. View

Qayyum M, Kwak J, Insana M . Stromal-epithelial responses to fractionated radiotherapy in a breast cancer microenvironment. Cancer Cell Int. 2015; 15:67. PMC: 4484641. DOI: 10.1186/s12935-015-0218-9. View

Schultz S, Bartsch H, Sotlar K, Petat-Dutter K, Bonin M, Kahlert S . Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers. BMC Med Genomics. 2018; 11(1):80. PMC: 6147035. DOI: 10.1186/s12920-018-0403-5. View

Thies K, Hammer A, Hildreth 3rd B, Steck S, Spehar J, Kladney R . Stromal Platelet-Derived Growth Factor Receptor-β Signaling Promotes Breast Cancer Metastasis in the Brain. Cancer Res. 2020; 81(3):606-618. PMC: 7581545. DOI: 10.1158/0008-5472.CAN-19-3731. View

Paulsson J, Sjoblom T, Micke P, Ponten F, Landberg G, Heldin C . Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol. 2009; 175(1):334-41. PMC: 2708819. DOI: 10.2353/ajpath.2009.081030. View

Stemke-Hale K, Gonzalez-Angulo A, Lluch A, Neve R, Kuo W, Davies M . An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008; 68(15):6084-91. PMC: 2680495. DOI: 10.1158/0008-5472.CAN-07-6854. View

Sagara Y, Freedman R, Vaz-Luis I, Mallory M, Wong S, Aydogan F . Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study. J Clin Oncol. 2016; 34(11):1190-6. PMC: 4872326. DOI: 10.1200/JCO.2015.65.1869. View

10.

Specks U, Mayer U, Nischt R, Spissinger T, Mann K, Timpl R . Structure of recombinant N-terminal globule of type VI collagen alpha 3 chain and its binding to heparin and hyaluronan. EMBO J. 1992; 11(12):4281-90. PMC: 557001. DOI: 10.1002/j.1460-2075.1992.tb05527.x. View

11.

Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M . Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011; 378(9804):1707-16. PMC: 3254252. DOI: 10.1016/S0140-6736(11)61629-2. View

12.

Prockop D . Mutations that alter the primary structure of type I collagen. The perils of a system for generating large structures by the principle of nucleated growth. J Biol Chem. 1990; 265(26):15349-52. View

13.

Baxevanis C, Fortis S, Perez S . The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies. Semin Cancer Biol. 2019; 72:76-89. DOI: 10.1016/j.semcancer.2019.12.018. View

14.

Ostman A . PDGF receptors in tumor stroma: Biological effects and associations with prognosis and response to treatment. Adv Drug Deliv Rev. 2017; 121:117-123. DOI: 10.1016/j.addr.2017.09.022. View

15.

Dong C, Wu J, Chen Y, Nie J, Chen C . Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. Front Pharmacol. 2021; 12:628690. PMC: 8005514. DOI: 10.3389/fphar.2021.628690. View

16.

Hanahan D, Coussens L . Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012; 21(3):309-22. DOI: 10.1016/j.ccr.2012.02.022. View

17.

Liu J, Shen J, Wu H, Li X, Wen X, Du C . Collagen 1A1 (COL1A1) promotes metastasis of breast cancer and is a potential therapeutic target. Discov Med. 2018; 25(139):211-223. View

18.

Hozhabri H, Ghasemi Dehkohneh R, Razavi S, Razavi S, Salarian F, Rasouli A . Comparative analysis of protein-protein interaction networks in metastatic breast cancer. PLoS One. 2022; 17(1):e0260584. PMC: 8769308. DOI: 10.1371/journal.pone.0260584. View

19.

Tekpli X, Lien T, Rossevold A, Nebdal D, Borgen E, Ohnstad H . An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment. Nat Commun. 2019; 10(1):5499. PMC: 6890706. DOI: 10.1038/s41467-019-13329-5. View

20.

Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi P . A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?. Cell. 2011; 146(3):353-8. PMC: 3235919. DOI: 10.1016/j.cell.2011.07.014. View